Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars
Pearce IP BioBlast®: w/e 25 June 2021

Pearce IP BioBlast®: w/e 25 June 2021

23 Jun 21 | US | Genentech announced that the FDA has accepted the BLA for its Port Delivery System with ranibizumab under Priority Review. Genentech is seeking approval for its PDS for the treatment of wet, or neovascular, age-related macular degeneration (AMD). 23...
Pearce IP BioBlast®: w/e 25 June 2021

Pearce IP BioBlast®: w/e 18 June 2021

10 June 21 | The UK’s NICE published final draft guidance recommending adalimumab, etanercept and infliximab for the treatment of moderate rheumatoid arthritis on the NHS. Previously, biologics had been recommended only for severe rheumatoid arthritis. 12 June...
Pearce IP BioBlast®: w/e 25 June 2021

Pearce IP BioBlast®: w/e 11 June 2021

07 Jun 21 | Celltrion launched Remsima SC® (subcutaneous infliximab biosimilar) in Canada.  Remsima SC® is indicated for the treatment of rheumatoid arthritis. 07 Jun 21 | Merck released new data on Keytruda® (pembrolizumab) in combination with Lenvima® (levatinib)...
Pearce IP BioBlast®: w/e 25 June 2021

Pearce IP BioBlast®: w/e 04 June 2021

31 May 21 | Celltrion will launch Yuflyma® (biosimilar adalimumab) in the EU in June, as reported by the Korea Herald.  Citing ‘industry sources’ and a Celltrion official, the Korea Herald discloses that Celltrion will initially launch Yuflyma® in six EU countries...
Pearce IP BioBlast®: w/e 25 June 2021

Pearce IP BioBlast®: w/e 28 May 2021

24 May 21 | IN | Zydus Cadila announced it has launched Ujvira (trastuzumab emtansine) in India. Ujvira is an antibody drug conjugate biosimilar and is available in 100mg and 160mg vials at a considerable discount to the reference product. 25 May 21 | BioFactura...